Reaction
Soft Tissue Injury reporting signals
As of the last recalculation, Soft Tissue Injury appears in 748 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is BOTULINUM TOXIN TYPE A (PRR 97.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Botulinum Toxin Type A | 41 | 97.2 | 97.5 |
| Lithium | 45 | 52.8 | 52.9 |
| Lithium Bromatum | 45 | 52.8 | 52.9 |
| Sumatriptan Succinate | 42 | 48.9 | 49.0 |
| Temazepam | 43 | 33.6 | 33.6 |
| Cyclobenzaprine | 47 | 27.9 | 27.9 |
| Naproxen | 63 | 24.3 | 24.3 |
| Erenumab-Aooe | 39 | 20.7 | 20.7 |
| Baclofen | 59 | 20.6 | 20.6 |
| Venlafaxine | 49 | 20.3 | 20.3 |
| Lamotirigine | 47 | 19.4 | 19.4 |
| Lamotrigine Extended-Release | 47 | 19.4 | 19.4 |
| Lamotrigine Chewable Dispersible | 47 | 19.4 | 19.4 |
| Sumatriptan | 25 | 18.9 | 18.9 |
| Dutasteride | 5 | 17.2 | 17.2 |
| Asfotase Alfa | 6 | 16.8 | 16.8 |
| Diclofenac Potassium, Film Coated | 4 | 13.3 | 13.3 |
| Diclofenac Potassium Tablets | 4 | 13.3 | 13.3 |
| Interferon Beta-1B | 8 | 11.7 | 11.7 |
| Onabotulinumtoxina | 31 | 11.6 | 11.6 |
| Canagliflozin | 12 | 11.3 | 11.3 |
| Diclofenac Potassium | 4 | 10.4 | 10.4 |
| Emicizumab | 3 | 6.8 | 6.8 |